850892-97-6

Basic information

• Product Name: tert-Butyl 4-broMo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate
• Synonyms: tert-Butyl 4-broMo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate;4-Bromo-1H-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester;4-BroMo-pyrrolo[2,3-c]pyridine-1-carboxylic acid tert-butyl ester
• CAS NO: 850892-97-6
• Molecular Formula: C₁₂H₁₃BrN₂O₂
• Molecular Weight: 297.14782
• Mol File: 850892-97-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.46
• CAS DataBase Reference: tert-Butyl 4-broMo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-broMo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate(850892-97-6)
• EPA Substance Registry System: tert-Butyl 4-broMo-1H-pyrrolo[2,3-c]pyridine-1-carboxylate(850892-97-6)

Safety Data

• Hazardous Substances Data: 850892-97-6(Hazardous Substances Data)

Upstream product

• 6627-89-0 tert-butyl phenyl carbonate 
• 69872-17-9 4-bromo-1H-pyrrolo[2,3-c]pyridine 
• 31872-65-8 3-bromo-5-nitropyridin-4-ol 
• 31872-63-6 3-bromo-4-chloro-5-nitropyridine 
• 69872-15-7 3-bromo-4-methyl-5-nitropyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 5435-54-1 4-hydroxy-3-nitropyridine 
• 69872-16-8 [2-(3-bromo-5-nitro-pyridin-4-yl)-vinyl]-dimethyl-amine 
• 69872-14-6 diethyl 2-(3-bromo-5-nitro-4-pyridyl)propanedioate 

Downstream Products

• 1578264-56-8 C₁₈H₁₆FN₃O₃ 
• 1578264-57-9 C₁₈H₁₆FN₃O₃ 
• 1578264-53-5 C₁₈H₁₆FN₃O₃ 
• 1578264-54-6 C₁₈H₁₆FN₃O₃ 
• 1578264-55-7 C₁₈H₁₆FN₃O₃ 

Relevant articles and documents

PYRIDINE DICARBOXAMIDE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.